Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.52 |
| ▸ | DPP4 | P27487 | 4/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094956 | 0.87 | GPR119 (0.57) | GPR119MEN1LMNAGAAKMT2A | |
| SCHEMBL4101971 | 0.87 | GPR119 (0.70) | GPR119 | |
| SCHEMBL4095100 | 0.85 | GPR119 (0.55) | GPR119DPP4DPP7LMNA | |
| SCHEMBL4214372 | 0.83 | GPR119 (0.60) | GPR119DPP4DPP7SMN1; SMN2 | |
| SCHEMBL4105880 | 0.80 | GPR119 (0.45) | GPR119 | |
| SCHEMBL4111525 | 0.79 | GPR119 (0.77) | GPR119DPP4DPP7 | |
| SCHEMBL4106773 | 0.79 | GPR119 (0.52) | GPR119 | |
| SCHEMBL2562243 | 0.78 | GPR119 (0.49) | GPR119SMN1; SMN2 | |
| SCHEMBL12283349 | 0.78 | GPR119 (0.49) | GPR119SMN1; SMN2 | |
| SCHEMBL10476647 | 0.78 | GPR119 (0.61) | GPR119DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013201-B1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LTD (GB) | 2012-07-25 | — | — | EP | claimed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | claimed |
| EP-2013201-B1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LTD (GB) | 2012-07-25 | — | — | EP | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221639-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GLP1R | GPR119 1/4885DPP4 775/4885DPP7 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.